PMID- 34349544
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231107
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 14
DP  - 2021
TI  - Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on 
      WHO Database.
PG  - 3909-3927
LID - 10.2147/IJGM.S324349 [doi]
AB  - BACKGROUND: Thirteen COVID-19 vaccines are granted emergency approval. It is 
      crucial to monitor their adverse events post vaccination. The present study 
      focuses on cardiovascular adverse events post-COVID-19 vaccination and aims to 
      determine adverse events with the administered vaccine. METHODOLOGY: The 
      cardiovascular (CVS) adverse events were extracted for three broad headings 
      (SOCs) - cardiac disorders, vascular disorders, and investigations. Descriptive 
      statistics were reported in the form of percentage and frequency, and the 
      disproportionality analysis was conducted. RESULTS: For the cardiovascular 
      system, 4863 adverse events (AEs) were reported from BNT162b2 Pfizer, 1222 
      AstraZeneca, Moderna, and other COVID-19 vaccines. Common adverse events observed 
      with vaccines under study were tachycardia (16.41%), flushing (12.17%), 
      hypertension (5.82%), hypotension (3.60%) and peripheral coldness (2.41%). Based 
      on disproportionality analysis (IC(025) values), acute myocardial infarction, 
      cardiac arrest, and circulatory collapse were linked to the vaccines in the age 
      group >75 years. Hypertension, severe hypertension, supraventricular tachycardia, 
      sinus tachycardia, and palpitations were associated across all age groups and 
      either gender. Amongst the investigations, abnormal ECG findings raised 
      C-reactive protein, elevated D dimer, and troponin were reported in specific age 
      groups or gender or all subjects. CONCLUSION: Although cardiovascular events have 
      been reported with the COVID-19 vaccines, the causality is yet to be established 
      because such CVS AEs are also usually associated with the general public even 
      without intervention. Hence, people should be administered these vaccines, and 
      sustained monitoring of these AEs should be done.
CI  - (c) 2021 Jeet Kaur et al.
FAU - Jeet Kaur, Rimple
AU  - Jeet Kaur R
AUID- ORCID: 0000-0003-4478-1411
AD  - Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, 
      Rajasthan, India.
FAU - Dutta, Siddhartha
AU  - Dutta S
AUID- ORCID: 0000-0001-6525-5950
AD  - Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, 
      Rajasthan, India.
FAU - Charan, Jaykaran
AU  - Charan J
AUID- ORCID: 0000-0002-4857-6725
AD  - Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, 
      Rajasthan, India.
FAU - Bhardwaj, Pankaj
AU  - Bhardwaj P
AUID- ORCID: 0000-0001-9960-3060
AD  - Department of Community and Family Medicine, All India Institute of Medical 
      Sciences (AIIMS), Jodhpur, Rajasthan, India.
FAU - Tandon, Ankita
AU  - Tandon A
AUID- ORCID: 0000-0002-7527-0772
AD  - Department of Oral Pathology, Microbiology and Forensic Odontology, Dental 
      Institute, Rajendra Institute of Medical Sciences, Ranchi, 834009, India.
FAU - Yadav, Dharamveer
AU  - Yadav D
AUID- ORCID: 0000-0002-7109-8039
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 
      Rajasthan, India.
FAU - Islam, Salequl
AU  - Islam S
AUID- ORCID: 0000-0001-6131-4132
AD  - Department of Microbiology, Jahangirnagar University, Savar, Dhaka, 1342, 
      Bangladesh.
FAU - Haque, Mainul
AU  - Haque M
AUID- ORCID: 0000-0002-6124-7993
AD  - Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti 
      Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem 
      Perdana Sungai Besi, 57000, Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20210727
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC8326931
OTO - NOTNLM
OT  - 1222 AstraZeneca
OT  - BNT162b2
OT  - COVID-19 vaccines
OT  - Moderna
OT  - adverse events
OT  - cardiovascular adverse events
COIS- The authors declare that they do not have any financial involvement or 
      affiliations with any organization, association, or entity directly or indirectly 
      with the subject matter or materials presented in this article. This also 
      includes honoraria, expert testimony, employment, ownership of stocks or options, 
      patents or grants received or pending, or royalties. The authors are responsible 
      for the views expressed in this paper, and they do not necessarily represent the 
      decisions, policy or views of the World Health Organization.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
PMCR- 2021/07/27
CRDT- 2021/08/05 06:22
PHST- 2021/06/11 00:00 [received]
PHST- 2021/07/14 00:00 [accepted]
PHST- 2021/08/05 06:22 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
PHST- 2021/07/27 00:00 [pmc-release]
AID - 324349 [pii]
AID - 10.2147/IJGM.S324349 [doi]
PST - epublish
SO  - Int J Gen Med. 2021 Jul 27;14:3909-3927. doi: 10.2147/IJGM.S324349. eCollection 
      2021.